ELVN Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Enliven Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.43 |
| 52 Week High | US$30.03 |
| 52 Week Low | US$10.90 |
| Beta | 0 |
| 1 Month Change | -3.91% |
| 3 Month Change | -11.02% |
| 1 Year Change | 84.76% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 2.84% |
Recent News & Updates
Shareholder Returns
| ELVN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 9.2% | -0.6% | -0.2% |
| 1Y | 84.8% | 3.0% | 25.8% |
Return vs Industry: ELVN exceeded the US Pharmaceuticals industry which returned 3% over the past year.
Return vs Market: ELVN exceeded the US Market which returned 25.8% over the past year.
Price Volatility
| ELVN volatility | |
|---|---|
| ELVN Average Weekly Movement | 6.7% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ELVN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ELVN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 57 | Sam Kintz | www.enliventherapeutics.com |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
Enliven Therapeutics, Inc. Fundamentals Summary
| ELVN fundamental statistics | |
|---|---|
| Market cap | US$1.19b |
| Earnings (TTM) | -US$85.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-14.0x
P/E RatioIs ELVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELVN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$85.21m |
| Earnings | -US$85.21m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ELVN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 05:45 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Enliven Therapeutics, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Justin Zelin | BTIG |
| Salveen Richter | Goldman Sachs |